Issue 16, 2016

Self-assembled nanospheres for encapsulation and aerosolization of rifampicin

Abstract

Rifampicin (RIF) is a benchmark drug for treatment of tuberculosis, but poor bioavailability, prolonged treatment, and pill burden have been linked to therapeutic failure and the development of multidrug resistant strains. To overcome these limitations, this study investigated a method of rifampicin nanoencapsulation and aerosol delivery using a commercial, hand-held nebulizer modified with a nitrogen stream.

Graphical abstract: Self-assembled nanospheres for encapsulation and aerosolization of rifampicin

Supplementary files

Article information

Article type
Communication
Submitted
25 Nov 2015
Accepted
21 Jan 2016
First published
26 Jan 2016

RSC Adv., 2016,6, 12959-12963

Author version available

Self-assembled nanospheres for encapsulation and aerosolization of rifampicin

A. A. Ishikawa, J. J. Velazquez Salazar, M. Salinas, C. M. Gaitani, T. R. Nurkiewicz, G. R. Negrete and C. D. Garcia, RSC Adv., 2016, 6, 12959 DOI: 10.1039/C5RA25044G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements